China Biopharma, Inc., a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced that OTC Financial Network, a division of National Financial Communications Corp., has issued an InvestorFacts Micro-Cap Stock Report on the Company. The report highlights the Company's product line of cutting-edge vaccines, industry catalysts, and management team and growth strategies.

An excerpt from the Micro-Cap Stock Report states, "With its management team, technology base, and strong market share in China, the Company is expertly positioned to capitalize on a biopharmaceutical industry ripe for consolidation. China Biopharma plans to acquire smaller-sized companies that offer complementary technologies and can enhance its product mix. Through international JV partnerships with industry leaders, CBPC plans to introduce breakthrough human-vaccine products to China, neighboring countries and other developed nations, including Europe and the United States. As a profitable company with impressive annual revenues, $10 million projected for 2006, China Biopharma seems to be a much-needed 'shot in the arm' for investors seeking an opportunity to maximize returns."

Source:佚名